TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice
- PMID: 9780163
TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice
Abstract
Nonobese diabetic (NOD) mice develop insulitis and diabetes through an autoimmune process. Since TGF-beta1 down-regulates many immune responses, we hypothesized that TGF-beta1 could prevent disease in NOD mice and that there would be several advantages to cytokine delivery by a somatic gene therapy approach. We opted for i.m. injection of a naked plasmid DNA expression vector encoding murine TGF-beta1 (pCMV-TGF-beta1). Treatment with pCMV-TGF-beta1 resulted in the retention and expression of the vector in muscle cells, associated with a considerable elevation in the plasma levels of TGF-beta1, that was not observed in control vector-treated mice. The levels of TGF-beta1 produced were sufficient to exert immunosuppressive effects. Delayed-type hypersensitivity responses were suppressed, and autoimmunity-prone NOD mice were protected from insulitis and diabetes in models of cyclophosphamide-accelerated and natural course disease. In pCMV-TGF-beta1-treated mice, pancreatic IL-12 and IFN-gamma mRNA expression was depressed, and the ratio of IFN-gamma to IL-4 mRNA was decreased, as determined by semiquantitative reverse-transcription PCR. In contrast, NOD mice injected with a vector encoding the proinflammatory cytokine IFN-gamma developed diabetes earlier. Intramuscular administration of cytokine-encoding plasmid vectors proved to be an effective method of cytokine delivery in these mice, and altered autoimmune disease expression.
Similar articles
-
Gene transfection and expression of transforming growth factor-beta1 in nonobese diabetic mouse islets protects beta-cells in syngeneic islet grafts from autoimmune destruction.Cell Transplant. 2002;11(6):519-28. Cell Transplant. 2002. PMID: 12428741
-
Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta1.J Clin Invest. 1998 Aug 1;102(3):499-506. doi: 10.1172/JCI2992. J Clin Invest. 1998. PMID: 9691086 Free PMC article.
-
Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes.J Immunol. 2011 Mar 15;186(6):3779-86. doi: 10.4049/jimmunol.1001422. Epub 2011 Feb 11. J Immunol. 2011. PMID: 21317396
-
Immune modulation by plasmid DNA-mediated cytokine gene transfer.Curr Pharm Des. 2003;9(1):83-94. doi: 10.2174/1381612033392404. Curr Pharm Des. 2003. PMID: 12570678 Review.
-
Anticytokine gene therapy of autoimmune diseases.Expert Opin Biol Ther. 2001 May;1(3):359-73. doi: 10.1517/14712598.1.3.359. Expert Opin Biol Ther. 2001. PMID: 11727511 Review.
Cited by
-
Gene therapy in the treatment of autoimmune diseases.J Clin Invest. 2000 Jul;106(2):181-3. doi: 10.1172/JCI10575. J Clin Invest. 2000. PMID: 10903332 Free PMC article. No abstract available.
-
Dietary flavonol epicatechin prevents the onset of type 1 diabetes in nonobese diabetic mice.J Agric Food Chem. 2013 May 8;61(18):4303-9. doi: 10.1021/jf304915h. Epub 2013 Apr 30. J Agric Food Chem. 2013. PMID: 23578364 Free PMC article.
-
Prevention of type 1 diabetes by gene therapy.J Clin Invest. 2004 Oct;114(7):969-78. doi: 10.1172/JCI22103. J Clin Invest. 2004. PMID: 15467836 Free PMC article.
-
The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.Clin Exp Immunol. 2010 Aug;161(2):250-67. doi: 10.1111/j.1365-2249.2010.04166.x. Epub 2010 May 18. Clin Exp Immunol. 2010. PMID: 20491795 Free PMC article.
-
CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.J Clin Invest. 2003 Sep;112(6):872-82. doi: 10.1172/JCI19112. J Clin Invest. 2003. PMID: 12975472 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical